Peter Neumann
LightNews LightNews
peterneumann11.bsky.social
Peter Neumann
@peterneumann11.bsky.social
140 followers 120 following 33 posts
Posts Replies Media Videos
Reposted by Peter Neumann
tuftscevr.bsky.social
Conversations about drug pricing/value benefit from launch price transparency. New CEVR research finds that, from 2022-2024, pharma companies disclosed 1/3 of drug launch prices proactively and another 1/3 reactively, suggesting room for improvement.

More at tinyurl.com/dsfjft4k
Communication of Launch Prices by Drug Companies, 2022-2024 | AJMC
Two-thirds of pharmaceutical companies did not proactively release the launch price of their medications from 2022 to 2024.
tinyurl.com
December 15, 2025 at 2:25 PM
peterneumann11.bsky.social
The best books I read in 2025. My annual list.

cevr.tuftsmedicalcenter.org/news/best-bo...
The Best Books I Read in 2025 - Center for the Evaluation of Value and Risk in Health
cevr.tuftsmedicalcenter.org
December 14, 2025 at 4:01 PM
Reposted by Peter Neumann
tuftscevr.bsky.social
What is the outlook for US payer coverage of specialty drugs in 2026? CEVR’s James Chambers will share insights from our SPEC database during a “can’t miss” webinar next week.

When: December 18, 12-12:30 pm ET

Register at tinyurl.com/56959f62
December 11, 2025 at 4:34 PM
peterneumann11.bsky.social
Our new @healthaffairs.bsky.social Forefront piece asks whether #Medicare's IPAY 2027 negotiated drug prices reflect value for money?

tinyurl.com/2hcn3uun @tuftscevr.bsky.social evr.bsky.social @djvanness.bsky.social
Do Medicare’s IPAY 2027 Negotiated Drug Prices Reflect Value For Money? | Health Affairs Forefront
Examining whether negotiated prices align with value is one way of asking if CMS “got pricing right” and if the Medicare program is getting its money’s worth.
tinyurl.com
December 11, 2025 at 2:51 PM
Reposted by Peter Neumann
tuftscevr.bsky.social
The Centers for Medicare and Medicaid Services (#CMS) recently released the maximum fair prices (#MFP) for the 15 #IPAY 2027 drugs. How closely do they align with value-based prices?

New CEVR research found wide variation, which sends muddled signals to drugmakers about value.

tinyurl.com/3jsuybc7
Do Medicare’s IPAY 2027 Negotiated Drug Prices Reflect Value For Money? | Health Affairs Forefront
Examining whether negotiated prices align with value is one way of asking if CMS “got pricing right” and if the Medicare program is getting its money’s worth.
tinyurl.com
December 11, 2025 at 1:32 PM
Reposted by Peter Neumann
tuftscevr.bsky.social
Some drugmakers are rolling out “pharm-to-table” programs to sell drugs directly to patients at lower costs, but how much will these programs to improve access and price transparency?

Read CEVR’s commentary on the promises and pitfalls of these programs.

tinyurl.com/mrv8dczp
The ‘Pharm-To-Table’ Movement For Prescription Drugs: Promising Or Performative? | Health Affairs Forefront
Direct-to-patient programs offer a glimpse of an alternative future in which the consumer or the employer is brought closer to the manufacturer of the medicine prescribed.
tinyurl.com
December 5, 2025 at 3:55 PM
peterneumann11.bsky.social
Is the "Pharm-to-Table" movement promising or performative?

@brianreid.bsky.social and I have thoughts today in @healthaffairs.bsky.social Forefront.

www.healthaffairs.org/content/fore...
The ‘Pharm-To-Table’ Movement For Prescription Drugs: Promising Or Performative? | Health Affairs Forefront
Direct-to-patient programs offer a glimpse of an alternative future in which the consumer or the employer is brought closer to the manufacturer of the medicine prescribed.
www.healthaffairs.org
December 5, 2025 at 1:46 PM
Reposted by Peter Neumann
tuftscevr.bsky.social
Only 25% of cost-effectiveness analyses published from 2013-23 (n=7,800) omit societal costs (productivity, caregiving, travel, etc.), despite consensus guidelines recommending their inclusion.

Read at tinyurl.com/3htu3zn9
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
tinyurl.com
December 1, 2025 at 3:57 PM
peterneumann11.bsky.social
Our new paper in Medical Decision Making finds that inclusion of societal costs in published cost-effectiveness analyses rose from 19%- 28% from 2013-2023, with variation across countries, diseases, & intervention types. @tuftscevr.bsky.social journals.sagepub.com/eprint/WBTRA... @smdm.bsky.social
When Do Published Cost-Effectiveness Analyses Include Societal Costs? An Empirical Analysis, 2013–2023 - Divya Patil, Bengt Liljas, Peter J. Neumann, Meng Li, 2025
Objective To examine trends in the inclusion of societal costs in published cost-effectiveness analyses (CEAs), factors associated with their inclusion, and the...
journals.sagepub.com
December 1, 2025 at 1:56 PM
peterneumann11.bsky.social
From QALYs to Equal Value Life Years: Is Anyone Making the Shift? Some thoughts with Antony Martin.

cevr.tuftsmedicalcenter.org/news/from-qa... @tuftscevr.bsky.social #HEOR #QALYs
From QALYs to Equal Value Life Years: Is Anyone Making the Shift? - Center for the Evaluation of Value and Risk in Health
cevr.tuftsmedicalcenter.org
October 16, 2025 at 12:49 PM
peterneumann11.bsky.social
Our new research letter in JAMA, led by James Chambers, highlights variation in how US commercial health plans impose coverage requirements for cell & #gene therapies.

jamanetwork.com/journals/jam... @tuftscevr.bsky.social
Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene Therapies
This Viewpoint examines variations in US commercial health plan coverage restrictions for cell and gene therapies.
jamanetwork.com
September 29, 2025 at 9:22 PM
peterneumann11.bsky.social
Pleased to join this distinguished group of authors in paying tribute to the great John Iglehart, founding editor of Health Affairs, who passed away in June.

tinyurl.com/47rnt9yf @tuftscevr.bsky.social @healthaffairs.bsky.social
Remembering John Iglehart, <i>Health Affairs</i> Founding Editor | Health Affairs Forefront
In this piece, we present remembrances of John from several of the countless people whose lives John touched personally and professionally.
tinyurl.com
September 24, 2025 at 12:31 PM
peterneumann11.bsky.social
New Tufts-CEVR research led by @pattysynnott.bsky.social highlights:
- high out-of-pocket costs of older adults living with dementia
- financial risks increase in advanced dementia states.

alz-journals.onlinelibrary.wiley.com/doi/10.1002/... #Alzheimers #dementia
Characterizing financial risk from out‐of‐pocket expenditures across dementia stages
INTRODUCTION Older adults with dementia incur considerable out-of-pocket (OOP) health care expenses, but it is unclear how their financial burden differs by dementia stage. METHODS We identified 2...
alz-journals.onlinelibrary.wiley.com
September 22, 2025 at 12:41 PM
peterneumann11.bsky.social
In this just published paper in Value in Health led by Feng Xie and colleagues, we reviewed the published cost-effectiveness evidence for the 15 drugs selected for IPAY 2027 Medicare negotiations.

@djvanness.bsky.social @ankurfactorial.bsky.social
www.valueinhealthjournal.com/article/S109...
Cost Effectiveness of the 15 Drugs Selected for IPAY 2027 CMS Drug Price Negotiation
To analyze published cost-effectiveness analyses (CEAs) for the 15 drugs selected for the Initial Price Applicability Year 2027 by the Centers for Medicare and Medicaid Services (CMS).
www.valueinhealthjournal.com
September 13, 2025 at 2:16 PM
Reposted by Peter Neumann
dano-hta.bsky.social
@icer-review.bsky.social @tuftscevr.bsky.social @peterneumann11.bsky.social @pattysynnott.bsky.social
August 4, 2025 at 9:10 PM
peterneumann11.bsky.social
Welcome, Dave!
tuftscevr.bsky.social CEVR @tuftscevr.bsky.social · Jul 29
CEVR is thrilled to welcome David Strutton, PhD, as a Senior Fellow! Dr. Strutton brings 30+ years of global leadership in health policy, biopharma, and HTA. His expertise in real-world evidence and access strategy will be a tremendous asset.

Read more at: tinyurl.com/3bz9te3p
David Strutton, PhD, to Join Tufts-CEVR as Senior Fellow - Center for the Evaluation of Value and Risk in Health
tinyurl.com
July 29, 2025 at 4:33 PM
Reposted by Peter Neumann
tuftscevr.bsky.social
CEVR is thrilled to welcome David Strutton, PhD, as a Senior Fellow! Dr. Strutton brings 30+ years of global leadership in health policy, biopharma, and HTA. His expertise in real-world evidence and access strategy will be a tremendous asset.

Read more at: tinyurl.com/3bz9te3p
David Strutton, PhD, to Join Tufts-CEVR as Senior Fellow - Center for the Evaluation of Value and Risk in Health
tinyurl.com
July 29, 2025 at 1:35 PM
peterneumann11.bsky.social
Excited to announce that David Strutton, Ph.D., a distinguished leader in healthcare policy, biopharmaceuticals, #vaccines, and #healtheconomics is joining Tufts-CEVR as a Senior Fellow.

Announcement here: cevr.tuftsmedicalcenter.org/news/david-s... @tuftscevr.bsky.social
July 29, 2025 at 2:41 PM
Reposted by Peter Neumann
tuftscevr.bsky.social
Great application of our CEA Registry at the #Vanderbilt Center for Health Economic Modeling: 11 international fellows from #LMICs used the Registry to conduct CEAs of public health interventions.

Read more at: tinyurl.com/88varaue

@peterneumann11.bsky.social #ISPOR
VUMC researchers host international fellows for economic evaluation, decision science training
Vanderbilt recently hosted 11 international fellows to provide training to help them address public health issues in their home countries.
tinyurl.com
July 23, 2025 at 8:12 PM
Reposted by Peter Neumann
tuftscevr.bsky.social
New in JCER: CEVR’s Meng Li and @peterneumann11.bsky.social call for more value assessment of health services/procedures. These interventions are ~70% of health care spending but are often implemented without robust evidence and, unlike drugs, can cost more over time.

Read: tinyurl.com/ycxrppby
Value assessment for health services and procedures: a call to action in a new political climate
tinyurl.com
July 21, 2025 at 4:32 PM
Reposted by Peter Neumann
tuftscevr.bsky.social
Two weeks left to apply: Earn your #HEOR Certificate online from @tufts.edu with globally-recognized faculty like @peterneumann11.bsky.social, @dano-hta.bsky.social, James Chambers, and more from CEVR. Apply today!

Deadline is Aug. 1.

tinyurl.com/pr6drkhf

#RWE #pharma
Health Economics and Outcomes Research (HEOR) Certificate Program - Tufts CTSI
Overview The Tufts University Graduate School of Biomedical Sciences (GSBS) Clinical and Translational Science (CTS) Graduate Program is delighted to offer an accredited Certificate Program in Health ...
tinyurl.com
July 18, 2025 at 6:13 PM
Reposted by Peter Neumann
tuftscevr.bsky.social
Larry Mose, MSc is today’s #CEARegistry Summer fellow. Larry earned his MSc from @york.ac.uk and hopes to work in the field of #HEOR.

Our thanks to the @moorefound.bsky.social ‬for funding the CEA Registry Fellowship program!‬‬
July 14, 2025 at 5:13 PM
Reposted by Peter Neumann
tuftscevr.bsky.social
1/ How closely do health plans’ drug #utilizationmanagement (UM) policies align with #clinicalguidelines? CEVR and NPC examined policies for 389 drug-indication pairs from 18 commercial insurers. Here’s a thread on what we found:
July 7, 2025 at 8:18 PM
peterneumann11.bsky.social
Some personal reflections about John Iglehart (1939-1975), Founding Editor of Health Affairs.

cevr.tuftsmedicalcenter.org/news/in-reme... @tuftscevr.bsky.social
In remembrance of John Iglehart - Center for the Evaluation of Value and Risk in Health
cevr.tuftsmedicalcenter.org
June 23, 2025 at 1:11 PM
peterneumann11.bsky.social
New Tufts-CEVR paper in the J of Alzheimer's Disease, led by Paige Lin, provides updated health utility estimates for persons with AD and their caregivers across disease stages and settings.

journals.sagepub.com/doi/10.1177/... @tuftscevr.bsky.social @pattysynnott.bsky.social #Alzheimers
June 20, 2025 at 3:47 PM